OvaScience Inc  

(Public, NASDAQ:OVAS)   Watch this stock  
Find more results for Mary McNeely�
-0.15 (-0.48%)
Real-time:   2:14PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 30.17 - 31.63
52 week 6.93 - 55.69
Open 31.06
Vol / Avg. 465,540.00/676,917.00
Mkt cap 865.93M
P/E     -
Div/yield     -
EPS -2.40
Shares 27.19M
Beta     -
Inst. own 98%
Aug 5, 2015
Q2 2015 OvaScience Inc Earnings Release (Estimated) Add to calendar
Jun 4, 2015
OvaScience Inc Annual Shareholders Meeting - 9:00AM EDT - Add to calendar
Jun 1, 2015
Ovascience Inc at Jefferies 2015 Global Healthcare Conference - 2:30PM EDT - Add to calendar
May 11, 2015
Q1 2015 OvaScience Inc Earnings Release
Mar 27, 2015
OvaScience Inc Corporate Call - AUGMENT KOL - Webcast
Mar 16, 2015
Q4 2014 OvaScience Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -114706.70% -
Operating margin -112086.70% -
EBITD margin - -
Return on average assets -57.19% -87.56%
Return on average equity -61.50% -102.08%
Employees 52 -
CDP Score - -


215 1st St Ste 240
CAMBRIDGE, MA 02142-1293
United States - Map
+1-617-5002802 (Phone)
+1-302-6554620 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


OvaScience, Inc. (OvaScience) is a global life sciences company. The Company is focused on the discovery, development and commercialization of new fertility treatments based on egg precursor or EggPC cells, which are immature egg cells found in the protective outer layer of a woman’s own ovaries. It offers AUGMENT Treatment. OvaScience’s treatment options under development include OvaPrime, OvaTure and OvaXon. With the AUGMENT treatment, energy-producing mitochondria from a patient’s own EggPC cells are added to the patient’s mature eggs during the IVF process to supplement the existing mitochondria. The AUGMENT treatment complements the standard of practice for an IVF cycle. OvaPrime treatment is a potential fertility treatment that could enable a woman to expand her egg reserve. OvaTure treatment is a potential next-generation IVF treatment that could help a woman produce healthy, young, fertilizable eggs without hormone injections.

Officers and directors

Richard H. Aldrich Independent Chairman of the Board
Age: 60
Bio & Compensation  - Reuters
Arthur Tzianabos Ph.D. President, Chief Scientific Officer
Age: 52
Bio & Compensation  - Reuters
Michelle Dipp M.D., Ph.D. Chief Executive Officer, Director
Age: 38
Bio & Compensation  - Reuters
Theresa McNeely Executive Vice President, Chief Communications Officer
Age: 51
Bio & Compensation  - Reuters
Jeffrey E. Young Chief Financial Officer, Treasurer
Age: 41
Bio & Compensation  - Reuters
David P. Harding Chief Commercial Officer
Age: 49
Bio & Compensation  - Reuters
Ravi Mehrotra Ph.D. Chief Corporate Development Officer
Bio & Compensation  - Reuters
John E. Sexton Ph.D. Director
Bio & Compensation  - Reuters
Jeffrey D. Capello Independent Director
Age: 50
Bio & Compensation  - Reuters
Mary M. Fisher Independent Director
Age: 53
Bio & Compensation  - Reuters